Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity

Authors, Journal, Affiliations, Type, DOI

Overview

TRIUMPH-1 randomized 2,339 adults with obesity and without diabetes to once-weekly retatrutide 4 mg, 9 mg or 12 mg or placebo for 80 weeks. With the treatment-regimen estimand, mean weight change was −17.6%, −23.7% and −25.0% versus −3.9% with placebo; with the efficacy estimand, up to −28.3%. In the 574 participants with knee osteoarthritis, WOMAC pain scores fell by 3.5–3.6 points at the 9- and 12-mg doses versus 1.9 with placebo, and in the 243 participants with obstructive sleep apnea the apnea–hypopnea index fell by 34.3 and 31.7 events per hour versus 9.9. The trial establishes retatrutide as the most potent obesity pharmacotherapy tested to date, at the cost of a dose-dependent gastrointestinal and neurological adverse-event profile.

Keywords

Retatrutide, triple hormone receptor agonist, GIP, GLP-1, glucagon, obesity, knee osteoarthritis, obstructive sleep apnea, cardiometabolic risk, randomized controlled trial

Key Takeaways

Background and Rationale

Methods

Participants

Body Weight

Knee Osteoarthritis

Obstructive Sleep Apnea

Cardiometabolic and Patient-Reported Outcomes

Safety

Interpretation

Limitations of the Document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated